Identifying herpes simplex virus keratitis in keratoconus surgery patients

Publication
Article
Ophthalmology Times EuropeOphthalmology Times Europe November 2022
Volume 18
Issue 09

One clinician advises investigating prospective patients for history and evidence suggesting HSV keratitis, and monitoring for post-surgery epithelial defects.

Reviewed by Dr David R. Hardten.

Identifying herpes simplex virus keratitis in keratoconus surgery patients

Nothing is perfect. Although corneal collagen cross-linking (CXL) to treat keratoconus is safe and stops the progression of disease, infections can occur. Herpes simplex virus (HSV) keratitis is one possibility, according to Dr David R. Hardten, from the Minnesota Eye Consultants in Minnetonka, Minnesota, United States.

Dr Hardten suggested that most cases of HSV keratitis associated with CXL are recurrences. He addressed the question of what causes HSV keratitis to recur and posited that the traumatic epi (epithelium)-off procedure, use of corticosteroids to reduce haze, and exposure to 30 minutes of ultraviolet light may be the culprits in re-stimulating the virus in patients with prior exposure.

He also noted that with the epi-on procedure, the epithelium is disrupted, which leaves the scene open for an HSV recurrence. “There are a number of different risk factors that can create that environment in which HSV can flourish,” he said.

Clinical plan to prevent HSV keratitis

Although HSV probably cannot be prevented all the time, a few things can be done that may preclude the development of HSV keratitis. The first is to examine the patient for scarring that may be present from a previous infection or from keratitis associated with contact lens wear.

Other options include asking the patient if they have a history of HSV and looking for evidence of previous atopic disease by comparing the two eyes. Dr Hardten stressed the importance of investigating history and looking for evidence of past HSV keratitis.

In patients with a history of disease, Dr Hardten pre-treats the eyes with an oral antiviral agent such as valaciclovir. This is administered three times daily about 1 week before the planned CXL procedure and then postoperatively in a tapering dosage.

“I still perform CXL in these patients,” he said. He estimates the risk in those with recurrent HSV to be similar to that in patients undergoing PRK and recommends performing the procedure because the benefits outweigh the risks. He proceeds by increasing the maintenance dose of the antiviral agent in those patients who had a previous infection.

The most important thing to watch for, Dr Hardten noted, is a postoperative persistent or enlarging epithelial defect. These defects are characterised by the presence of geographic ulcers that have a broader base than the typical narrower dendrites one would see with HSV in patients not taking corticosteroids.

The risks associated with administering an antiviral agent to these patients are very low, he commented. Nevertheless, Dr Hardten advised physicians to proceed with caution. “I think that CXL is relatively safe,” he explained. “However, there are some potential complications.”

Dr Hardten concluded, “Consider increasing the maintenance dose if patients are already receiving maintenance antiviral therapy. Prophylaxis therapy is appropriate if you are suspicious. Be wary of epithelial defects; if they are slow to close, consider geographic ulcers. If healing does not occur in 4–5 days, consider that this may be HSV keratitis.”

David R. Hardten, MD
E: drhardten@mneye.com
This article is adapted from Dr Hardten’s presentation at the recent annual meeting of the American Society of Cataract and Refractive Surgery in Washington, DC, United States. He is a consultant to Glaukos.
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.